OTCMKTS:UCBJY UCB (UCBJY) Stock Price, News & Analysis $96.36 -0.12 (-0.12%) As of 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesSEC FilingsShort InterestBuy This Stock About UCB Stock (OTCMKTS:UCBJY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get UCB alerts:Sign Up Key Stats Today's Range$95.75▼$96.5550-Day Range$75.96▼$106.6052-Week Range$63.58▼$106.60Volume113,191 shsAverage Volume44,213 shsMarket Capitalization$36.43 billionP/E RatioN/ADividend Yield0.50%Price TargetN/AConsensus RatingN/A Company OverviewUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More… Receive UCBJY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address UCBJY Stock News HeadlinesTD Cowen maintains UCB stock Buy rating, EUR250 targetMarch 27, 2025 | uk.investing.comUCB SA (UCBJY)February 2, 2025 | finance.yahoo.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 5, 2025 | Crypto 101 Media (Ad)UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)January 17, 2025 | finance.yahoo.comUCB (OTC:UCBJY) Stock Quotes, Forecast and News SummaryNovember 22, 2024 | benzinga.comFDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin DiseaseNovember 20, 2024 | benzinga.comBiogen, UCB release phase 3 data on lupus candidate dapirolizumabNovember 19, 2024 | msn.comOruka draws buy at Stifel on potential against psoriasisOctober 11, 2024 | msn.comSee More Headlines UCBJY Stock Analysis - Frequently Asked Questions How have UCBJY shares performed this year? UCB's stock was trading at $98.85 at the beginning of 2025. Since then, UCBJY shares have decreased by 2.5% and is now trading at $96.36. View the best growth stocks for 2025 here. How do I buy shares of UCB? Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Ex-Dividend for 5/14 Dividend4/28/2025Record date for 5/14 Dividend4/29/2025Today5/05/2025Dividend Payable5/14/2025Next Earnings (Estimated)7/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:UCBJY Previous SymbolOTCMKTS:UCBJY CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees9,083Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio37.98 P/E Growth0.69Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.33 Current Ratio1.19 Quick Ratio0.78 Sales & Book Value Annual Sales$5.27 billion Price / Sales6.92 Cash Flow$4.04 per share Price / Cash Flow23.88 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares378,040,000Free FloatN/AMarket Cap$36.47 billion OptionableNot Optionable Beta0.53 Social Links 20 Stocks to Sell NowGet This Free Report This page (OTCMKTS:UCBJY) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Share UCB With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.